Should you buy Collegium Pharmaceutical (COLL)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Exceptional Cash Conversion Quality→Stable
- Deep Value Wide Analyst Gap→Stable
- High Short Interest Squeeze Setup→Stable
- +1 more pillar — see the Why tab for full reasoning
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Exceptional Cash Conversion Quality
Trip ifFree cash flow falls below 100% of reported net income for 2 consecutive fiscal quarters, indicating the cash conversion premium has materially compressed.
- P2Deep Value Wide Analyst Gap
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, undermining the earnings-growth premise required to close the valuation gap to $47.27.
- P3High Short Interest Squeeze Setup
Trip ifShort interest rises above 30% of the float for 2 consecutive months, indicating the fundamental bear case is strengthening rather than approaching exhaustion.
- P4Leverage Mixed Earnings Headwind
Trip ifDebt-to-equity ratio rises above 4x, increasing financial leverage risk materially beyond the current 3.0x level.
How the engine reached this verdict
TrendMatrix's engine output for Collegium Pharmaceutical, Inc. (COLL) is SELL_IF_HOLDING with medium conviction, score 6.4/10 at $37.47. The F-path SELL output reflects an overall score of 4.9 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 1.74 is supplementary context, not the trigger.
The engine's exit framework anchors to a tactical sell band near $37.47, with structural invalidation at $34.85. The asymmetric R:R against a reversal hypothesis is 1.74 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bull side: High-quality business; Attractive valuation; Strong growth profile. On the bear side: Concentration risk — Supplier: API sole or limited-source suppliers; Concentration risk — Supplier: Patheon (contract manufacturer for Xtampza ER and Nucynta ER); Leverage penalty (D/E 3.0): -1.5.
SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates COLL — 10-dimension breakdown →
Bull case
- ▸High-quality business
- ▸Attractive valuation
- ▸Strong growth profile
Bear case
- ▸Concentration risk — Supplier: API sole or limited-source suppliers
- ▸Concentration risk — Supplier: Patheon (contract manufacturer for Xtampza ER and Nucynta ER)
- ▸Leverage penalty (D/E 3.0): -1.5